ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, B.
Right arrow Articles by Jing, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, B.
Right arrow Articles by Jing, H.
Annals of Clinical & Laboratory Science 35:161-168 (2005)
© 2005 Association of Clinical Scientists

Recombinant Human Erythropoietin Pretreatment Attenuates Myocardial Infarct Size: A Possible Mechanism Involves Heat Shock Protein 70 and Attenuation of Nuclear Factor-kappaB

Biao Xu1, Guo-hua Dong1, Hong Liu1, Yan-qing Wang2, Hai-wei Wu1 and Hua Jing1
1 Department of Cardiothoracic Surgery and 2 Department of Cardiology, Jingling Hospital, Nanjing University Medical School, Nanjing, People’s Republic of China

Address correspondence to Biao Xu, M.D., Department of Cardiovascular Surgery, Jinling Hospital, 305 East Zhongshan Road, Nanjing 210002, People’s Republic of China; tel 86 25 8481 9984; fax 86 25 8480 6839; e-mail xubiao3000{at}msn.com.

Erythropoietin (EPO), known for its role in stimulating erythropoiesis, has recently been shown to have a cardio-protective effect in animal models of myocardial ischemia-reperfusion (I-R) injury. The mechanism of the cardio-protective effect of EPO is unclear. Part of the mechanism for EPO-induced cardio-protection may involve inhibition of myocardial apoptosis and preservation of ATP levels in the ischemic myocardium. We studied the expression of heat shock protein 70 (Hsp70) and its possible links to the cardio-protective effect of EPO. A rat model of myocardial I-R injury was established by ligating the left descending coronary artery for 30 min and then reperfusing for 2 hr. Recombinant human EPO (rhEPO) was injected ip 24 hr before the ligation. The myocardial infarct size and the area at risk of ischemia were measured by staining with triphenyltetrazolium chloride (TTC) and Evans blue dye. Expression of Hsp70 in the left ventricle was analyzed by ELISA and that of nuclear factor-kappaB (NF-{kappa}B) was analyzed by electrophoretic mobility shift assay (EMSA). The results showed that a single ip injection of 3,000 units/kg of rhEPO at 24 hr pre-ligation enhanced the expression of Hsp70 and diminished the expression of NF-{kappa}B in rat myocardium, and that the myocardial infarct induced by I-R injury was remarkably reduced in size, compared to control rats that received an ip saline injection at 24 hr pre-ligation.

Keywords: apoptosis, erythropoietin, Hsp70, NF-{kappa}B, ischemia-reperfusion injury, myocardial infarction




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
S. Reuter, P. Bangen, B. Edemir, U. Hillebrand, H. Pavenstadt, S. Heidenreich, and D. Lang
The HSP72 stress response of monocytes from patients on haemodialysis is impaired
Nephrol. Dial. Transplant., April 1, 2009; (2009) gfp142v1.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
Y. Yokomaku, T. Sugimoto, S. Kume, S.-i. Araki, K. Isshiki, M. Chin-Kanasaki, M. Sakaguchi, N. Nitta, M. Haneda, D. Koya, et al.
Asialoerythropoietin Prevents Contrast-Induced Nephropathy
J. Am. Soc. Nephrol., February 1, 2008; 19(2): 321 - 328.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
H. Wu, B. Ren, J. Zhu, G. Dong, B. Xu, C. Wang, X. Zheng, and H. Jing
Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats.
Eur. J. Cardiothorac. Surg., June 1, 2006; 29(6): 902 - 907.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the Association of Clinical Scientists.